Guardant Health, Inc.
GH
Classement en actions
#1081
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Prix de l'action
$161.19
Capitalisation boursière
$21.63B
Changement (1 jour)
2.10%
Changement (1 an)
129.62%
Pays
US
Échange Guardant Health, Inc. (GH)
Catégorie
Healthcare
Bénéfices pour Guardant Health, Inc. (GH)
Bénéfices en Jun 2026 TTM : $-454.47M
Selon les derniers rapports financiers de Guardant Health, Inc., les bénéfices actuels de l'entreprise sont de $-454.47M. En 2023, l'entreprise a réalisé un bénéfice de $-478.76M, une augmentation par rapport à celui de 2022 qui était de $-653.45M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Guardant Health, Inc. de 2016 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-454.47M | 4.45% |
| 2024 | $-435.09M | -9.12% |
| 2023 | $-478.76M | -26.73% |
| 2022 | $-653.45M | 69.96% |
| 2021 | $-384.47M | 56.35% |
| 2020 | $-245.90M | 252.69% |
| 2019 | $-69.72M | -17.22% |
| 2018 | $-84.23M | 1.21% |
| 2017 | $-83.21M | 80.38% |
| 2016 | $-46.13M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $7.61B | -1,774.26% |
US
|
|
| $4.76B | -1,147.81% |
US
|
|
| $-252.70M | -44.40% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -464.82% |
US
|
